Dare Bioscience, INC. 8-K Filing

Key Financial Figures

• $1.0 million — to the License Agreement, we received a $1.0 million upfront non-refundable license fee paym

Filing Documents

• form8-k.htm (8-K) — 50KB
• ex99-1.htm (EX-99.1) — 31KB
• 0001493152-25-025491.txt ( ) — 257KB
• dare-20251126.xsd (EX-101.SCH) — 3KB
• dare-20251126_lab.xml (EX-101.LAB) — 33KB
• dare-20251126_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will,"

Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," "on track," or the negative version of these words and similar expressions. In this report, forward-looking statements include, but are not limited to, statements relating to our expectation that the termination of the License Agreement will not have a material impact on ongoing pivotal Phase 3 clinical study of Ovaprene and that enrollment in such study will be completed in 2026. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Dar's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this report, including, without limitation, risks and uncertainties related to: Dar's ability to design and conduct successful clinical trials, to enroll a sufficient number of patients, to meet established clinical endpoints, to avoid undesirable side effects and other safety concerns, and to demonstrate sufficient safety and efficacy of its product candidates; Dar's dependence on third parties, including to conduct clinical and nonclinical studies and manufacture and supply clinical trial material and commercial product; the risks that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate and that interim data or results from a particular clinical study do not necessarily predict the final results for that study; the risk that the FDA, other regulatory authorities, members of the scientific or medical communities or investors may not accept or agree with Dar's interpretation of or conclus

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press release issued on December 1, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -3-

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DAR BIOSCIENCE, INC. Dated: December 1, 2025 By: /s/ Sabrina Martucci Johnson Name: Sabrina Martucci Johnson Title: President and Chief Executive Officer -4-

View Full Filing

View this 8-K filing on SEC EDGAR